RxDoctor Payments Data

Marc Levin, MD

Ophthalmology · Palo Alto, CANPI 1811123441

Payments from drug & device makers

$53,640in general payments, 2019–2025

Across 25 payments — averaging $2145.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$53K
  • AbbVie$412
  • Vanda Pharmaceuticals Inc.$229
$255,250in research payments, 2019–2025

Across 65 payments — averaging $3926.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vanda Pharmaceuticals Inc.$255K

What the payments were for

  • Consulting fees$53,00099%
  • Food & beverage$6401%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Jazz Pharmaceuticals Inc.19$53,000
AbbVie3$412
Vanda Pharmaceuticals Inc.3$229

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,640 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$50,140
Medicare patients
211
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pyridostigmine Bromide13$1,035
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha26$770
Latanoprost14$89
Prednisone11$88

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →